But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
Look out Amryt: Krystal’s topical gene therapy is gaining ground.
Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Despite concerns about a missing patient, results from a tiny trial in epidermolysis bullosa boosted Krystal Biotech’s stock by 41%.
Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.